卵巢癌组织中Toll样受体9的表达及其临床意义

目的 检测Toll样受体9(TLR9)在卵巢癌组织中的表达,并探讨其临床意义.方法 采用免疫组织化学和Western blot方法检测30例卵巢癌组织及其癌旁组织、30例正常卵巢组织中TLR9的表达,并分析TLR9的表达与卵巢癌临床病理特征的关系.结果 免疫组织化学检测结果表明,卵巢癌组织、癌旁组织和正常卵巢组织中,TLR9蛋白的阳性表达率分别为80.0%、36.7%和20.0%,卵巢癌组织TLR9的阳性表达率高于正常卵巢组织和癌旁组织(均P＜0.01).TLR9蛋白的表达与肿瘤分化程度、国际妇产科协会(FIGO)分期、淋巴结转移有关(P＜0.05).Western blot检测结果显示,卵巢癌组织、癌旁组织和正常卵巢组织的相对表达量分别为0.803±0.072、0.411±0.087和0.113±0.065,卵巢癌组织中TLR9的表达量明显高于相应的癌旁组织及正常卵巢组织(均P＜0.01).结论 TLR9在卵巢癌组织中高表达,且TLR9的表达与卵巢癌的病理分级有关,提示TLR9可能通过免疫机制参与卵巢癌的发生、发展过程.

Expression and clinical significance of TLR9 in ovarian cancer

Objective To detect the expression of Toll-like receptor 9(TLR9)in ovarian cancer,and to explore their clinical significance. Methods Western blot method and immunohistochemical staining were used to examine the expression of TLR9 in the ovarian cancer, paracancerous tissues and normal ovarian tissues, obtained during operation from 30 ovarian carcinoma patients and 30 normal non-tumor patients. The relationships of TLR9 with pathological grade, clinical stage, and metastasis of ovarian cancer were statistically analyzed. Results The percentage of positive cells expressing TLR9 protein in human ovarian cancer tissues, paracancerous tissues and normal ovarian tissues were 80.0%, 36.7% and 20.0%,respectively. The protein expression level of TLR9 was gradually descending(P ＜ 0. 01). The highly expressed TLR9 significantly correlated with the degree of tumor differentiation, an advanced FIGO stage and lymph node metastasis. The Western blot results showed that TLR9 protein expression in ovarian cancer,paracancerous tissues and normal ovarian tissues were 0.803 ±0.072, 0.411±0.087 and 0.113 ±0. 065,respectively. The expression of TLR9 in ovarian cancer was significantly higher than that in normal tissue and paracancerous tissues(P ＜ 0. 01). Conclusions TLR9 has a higher expression in ovarian cancer tissues.TLR9 expression has a close relationship with pathological grades of ovarian cancer, suggesting that TLR9 plays an important role in the development and progression of ovarian cancer through immunologic mechanisms.